Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-10-05
2011-11-01
Spivack, Phyllis G. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
08048928
ABSTRACT:
A method for treating a liver disease such as hepatitis, comprising administering to a patient having the liver disease, an effective amount of a diarylsulfide or diarylether derivative having 2-amino-1,3-propanediol structure, and represented by the following formula (1):or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 5447922 (1995-09-01), Lawrence et al.
patent: 5604229 (1997-02-01), Fujita et al.
patent: 5948820 (1999-09-01), Fujita et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6214873 (2001-04-01), Adachi et al.
patent: 6489331 (2002-12-01), Shimada et al.
patent: 6531505 (2003-03-01), Xu et al.
patent: 6667025 (2003-12-01), Chiba et al.
patent: 6960692 (2005-11-01), Kohno et al.
patent: 6963012 (2005-11-01), Kohno et al.
patent: 7456157 (2008-11-01), Kohno et al.
patent: 7482491 (2009-01-01), Kohno et al.
patent: 7781617 (2010-08-01), Kudou et al.
patent: 7807854 (2010-10-01), Kudou et al.
patent: 2002/0040050 (2002-04-01), Xu et al.
patent: 2002/0091105 (2002-07-01), Mandala et al.
patent: 2002/0143034 (2002-10-01), Taniguchi et al.
patent: 2003/0069168 (2003-04-01), Xu et al.
patent: 2003/0236297 (2003-12-01), Nishi et al.
patent: 2004/0058894 (2004-03-01), Doherty et al.
patent: 2004/0067908 (2004-04-01), Nakade et al.
patent: 2004/0087662 (2004-05-01), Bigaud et al.
patent: 2004/0110728 (2004-06-01), Macdonald et al.
patent: 2004/0138462 (2004-07-01), Sakurai et al.
patent: 2004/0147490 (2004-07-01), Albert et al.
patent: 2004/0224941 (2004-11-01), Seko et al.
patent: 2004/0235794 (2004-11-01), Nakade et al.
patent: 2004/0242654 (2004-12-01), Kohno et al.
patent: 2004/0248952 (2004-12-01), Pan et al.
patent: 2004/0254222 (2004-12-01), Kohno et al.
patent: 2005/0009786 (2005-01-01), Pan et al.
patent: 2005/0020837 (2005-01-01), Doherty et al.
patent: 2005/0033055 (2005-02-01), Bugianesi et al.
patent: 2005/0043386 (2005-02-01), Nishi et al.
patent: 2005/0107345 (2005-05-01), Doherty et al.
patent: 2005/0222422 (2005-10-01), Lynch et al.
patent: 2005/0245575 (2005-11-01), Chen et al.
patent: 2006/0046979 (2006-03-01), Foster et al.
patent: 2006/0089334 (2006-04-01), Budhu et al.
patent: 2006/0135622 (2006-06-01), Kohno et al.
patent: 2006/0135786 (2006-06-01), Saha et al.
patent: 2006/0148830 (2006-07-01), Terakado et al.
patent: 2006/0148844 (2006-07-01), Nakade et al.
patent: 2006/0160771 (2006-07-01), Kohno et al.
patent: 2006/0161005 (2006-07-01), Doherty et al.
patent: 2006/0166940 (2006-07-01), Buehlmayer et al.
patent: 2006/0211656 (2006-09-01), Albert et al.
patent: 2006/0211658 (2006-09-01), Hinterding et al.
patent: 2006/0252741 (2006-11-01), Colandrea et al.
patent: 2006/0264403 (2006-11-01), Albert
patent: 2007/0010494 (2007-01-01), Ehrhardt et al.
patent: 2007/0043014 (2007-02-01), Doherty et al.
patent: 2007/0088002 (2007-04-01), Lynch et al.
patent: 2007/0135501 (2007-06-01), Hinterding et al.
patent: 2007/0149597 (2007-06-01), Nishi et al.
patent: 2007/0167410 (2007-07-01), Pan et al.
patent: 2007/0167425 (2007-07-01), Nakade et al.
patent: 2007/0191468 (2007-08-01), Nishi et al.
patent: 2007/0203100 (2007-08-01), Pan et al.
patent: 2007/0225260 (2007-09-01), Hinterding et al.
patent: 2008/0025973 (2008-01-01), Fleenor et al.
patent: 2008/0027508 (2008-01-01), Chu
patent: 2008/0032923 (2008-02-01), Kudou et al.
patent: 2008/0153882 (2008-06-01), Nishi et al.
patent: 2008/0161410 (2008-07-01), Kusters et al.
patent: 2008/0200438 (2008-08-01), Albert et al.
patent: 2008/0207584 (2008-08-01), Habashita et al.
patent: 2008/0207941 (2008-08-01), Tsubuki et al.
patent: 2008/0249093 (2008-10-01), Colandrea et al.
patent: 2009/0023797 (2009-01-01), Azzaoui et al.
patent: 2000-154151 (2000-06-01), None
patent: 2002-53575 (2002-02-01), None
patent: 2002-316985 (2002-10-01), None
patent: 2003-137894 (2003-05-01), None
patent: 2003-267936 (2003-09-01), None
patent: 2004-137208 (2004-05-01), None
patent: 2004-307439 (2004-11-01), None
patent: 2004-307440 (2004-11-01), None
patent: 2004-307441 (2004-11-01), None
patent: 2004-307442 (2004-11-01), None
patent: 2005-47899 (2005-02-01), None
patent: 2005-247691 (2005-09-01), None
patent: 01/98301 (2001-12-01), None
patent: 03/029184 (2003-04-01), None
patent: 03/029205 (2003-04-01), None
patent: 2005/014525 (2005-02-01), None
patent: 2005/014603 (2005-02-01), None
patent: 2005/063671 (2005-07-01), None
patent: 2006/041015 (2006-04-01), None
patent: 2006/063033 (2006-06-01), None
patent: 2006/129688 (2006-12-01), None
patent: 2007/043433 (2007-04-01), None
patent: 2007/043568 (2007-04-01), None
patent: 2007/091501 (2007-08-01), None
Vippagunta (Adv. Drug Del. Rev., 2001, vol. 48, 2001, pp. 3-26.
Rakela, BJ, Rev. Med. Chil., (Apr. 2010); 138(4):504-10 (abstract).
Tovoli et al., Case Rep. Gastroenterology, (Oct. 2010); 4(3):469-475 (Abstract).
The Merck Manual, 17thedition, (1999), pp. 343-344.
International Search Report issued Nov. 28, 2006 in the International (PCT) Application PCT/JP2006/319961of which the present application is the U.S. National Stage.
Don Ganem et al., “The Molecular Biology of the Hepatitis B Viruses”, Annual Review Biochem., 56, pp. 651-693, 1987.
I Saito et al., “Hepatitis C virus infection is associated with the development of hepatocellular carcinoma”, Proc. Natl. Acad. Sci., USA, vol. 87, pp. 6547-6549, Sep. 1990.
Mark E. Mailliard et al., “Suppressing Hepatitis B without Resistance—So Far, So Good”, The New England Journal of Medicine, pp. 848-850, Feb. 27, 2003.
Michael W. Fried et al., “Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus infection”, New England Journal of Medicine, vol. 347, No. 13, pp. 975-982, Sep. 26, 2002.
Francis V. Chisari, “Perspectives Series: Host/Pathogen Interactions”, J. Clin. Invest., vol. 99, No. 7, pp. 1472-1477, Apr. 1997.
Takashi Kaneko et al., “Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice”, Biochemical and Biophysical Research Communications, vol. 345, pp. 85-92, 2006.
Rei Tsunematsu et al., “ConA Kan Shogai ni Okeru Men'eki Yokuseizai FTY720 no Koka ni Kansuru Kento”, Acta Hepatologica Japonica, vol. 46, No. Supplement 2, p. A445, ‘Kan P-207’, Sep. 2005.
Michael A. Heneghan et al., “Current and Novel Immunosuppresive Therapy for Autoimmune Hepatitis”, Hepatology, vol. 35, pp. 7-13, 2002.
Blam et al., Integrating Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Current and Future Perspectives, Am. J. Gastroenterology, 2001, vol. 96, No. 7, pp. 1977-1997.
Keller et al., Immunomodulator FTY720 Induces Myofibroblast Differentiation via the Lysophospholipid Receptor S1P3 and Smad3 Signaling, Am. J. Pathology, Jan. 2007, vol. 170, No. 1, pp. 281-292.
Yasuyuki Igarashi, Sphingosine-1-Phosphate as an Intercellular Signaling Molecule, Ann. NY Acad. Sci., 1998, vol. 845, pp. 19-31.
Jacobs et al., Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis, Ann. Neurol., 1996, vol. 39, No. 3, pp. 285-294.
Weinshenker et al., A Randomized Trial of Plasma Exchange in Acute Central Nervous System Inflammatory Demyelinating Disease, Ann. Neurol., 1999, vol. 46, No. 6, pp. 878-886.
Okazaki et al., Molecular Cloning of a Novel Putative G Protein-Coupled Receptor Expressed in the Cardiovascular System, Biochem. and Biophys. Res. Commun., 1993, vol. 190, No. 3, pp. 1104-1106.
Klein et al., Total Synthesis and Antifungal Evaluation of Cyclic Aminohexapeptides, Bioorg. Med. Chem., 2000, vol. 8, pp. 167-1696.
Hashimoto et al., β-Phenylselenoalanine as a dehydroalanine precursor-efficient synthesis of alternariolide (AM-toxin I), Chem. Commun., 1996, pp. 1139-1140.
Levkau et al., High-Density Lipoprotein Stimulates Myocardial Perfusion in Vivo, Circulation, 2004, vol. 110, pp. 3355-3359.
Salomone et al., S1P3receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate, Eur. J. Pharmacol., 2003, vol. 469, pp. 125-134.
Kiuchi et al., Synthesis and Immunosuppressive Activity o
Kaneko Takashi
Kobayashi Eiji
Yasue Tokutarou
Kyorin Pharmaceutical Co. Ltd.
Spivack Phyllis G.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Therapeutic agent for treating liver disease containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for treating liver disease containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for treating liver disease containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4279791